--- title: "These Analysts Revise Their Forecasts On BioMarin Pharmaceutical After Q4 Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/276922251.md" description: "BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported mixed Q4 results, with earnings of 46 cents per share missing estimates of 63 cents, but sales of $875 million exceeding expectations of $827 million. The company forecasts FY2026 sales between $3.325 billion and $3.425 billion, below market estimates. Analysts revised price targets post-earnings: HC Wainwright lowered to $55, Guggenheim to $86, and Bernstein raised to $94. BMRN shares fell 1.7% to $61.54." datetime: "2026-02-25T17:44:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276922251.md) - [en](https://longbridge.com/en/news/276922251.md) - [zh-HK](https://longbridge.com/zh-HK/news/276922251.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276922251.md) | [繁體中文](https://longbridge.com/zh-HK/news/276922251.md) # These Analysts Revise Their Forecasts On BioMarin Pharmaceutical After Q4 Results **Biomarin Pharmaceutical Inc** (NASDAQ:BMRN) reported mixed results for the fourth quarter after the closing bell on Monday. The company posted quarterly earnings of 46 cents per share which missed the analyst consensus estimate of 63 cents per share. The company reported quarterly sales of $875.000 million which beat the analyst consensus estimate of $827.969 million. BioMarin Pharmaceutical said it sees FY2026 sales of $3.325 billion-$3.425 billion, versus market estimates of $3.507 billion. “In 2025, operational excellence led to strengthening financial results, including double-digit topline growth, strong profitability and increasing cash flow. We also advanced multiple medicines in our pipeline and closed the year by announcing the acquisition of Amicus,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. “The Amicus transaction, which is expected to close in the second quarter, represents a compelling opportunity to reach more patients around the world and further strengthen our revenue growth through the next decade.” BMRN shares fell 1.7% to trade at $61.54 on Wednesday. These analysts made changes to their price targets on BMRN following earnings announcement. - HC Wainwright & Co. analyst Mitchell S. Kapoor maintained BioMarin Pharmaceutical with a Neutral and lowered the price target from $60 to $55. - Guggenheim analyst Debjit Chattopadhyay maintained the stock with a Buy and lowered the price target from $106 to $86. - Bernstein analyst William Pickering maintained BioMarin Pharmaceutical with an Outperform rating and raised the price target from $90 to $94. **Considering buying CL stock? Here’s what analysts think:** Photo via Shutterstock ### Related Stocks - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [BioMarin Pharmaceutical Inc. (BMRN.US)](https://longbridge.com/en/quote/BMRN.US.md) - [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [Faron Pharmaceuticals Ltd: Director Dealing](https://longbridge.com/en/news/281133676.md) - [Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00](https://longbridge.com/en/news/281425457.md) - [Glenmark Pharma to directly commercialize and distribute Ryaltris in U.S. effective](https://longbridge.com/en/news/281370208.md) - [Insider Confidence Surges as Tivic Health Systems Director Doubles Down](https://longbridge.com/en/news/281595239.md) - [OMER S.p.A.: Resilient Fundamentals and Structural Growth Support Buy Rating Despite Softer FY26 Outlook](https://longbridge.com/en/news/281649119.md)